Evidence map›Paper›PMID 23661019›Full record

ArticleMolecular biology reports2013

Ewing Sarcoma: influence of TP53 Arg72Pro and MDM2 T309G SNPs.

Helena S Thurow, Fernando P Hartwig, Clarice S Alho, Deborah S B S Silva, Rafael Roesler, Ana Lucia Abujamra, Caroline Brunetto de Farias, Algemir Lunardi Brunetto, Bernardo L Horta, Odir A Dellagostin and 2 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 3 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Impact of MDM2 gene polymorphism on sarcoma risk.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Pooled it
  3. Association between p53 codon 72 polymorphism and sarcoma risk among Caucasians.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Pooled it
  4. Article
  5. Polymorphic variants ofFrontiers in oncology · 2022
    Article
  6. Review: Ewing Sarcoma Predisposition.Pathology oncology research : POR · 2020
    Review
  7. Article
  8. Article
  9. Polymorphisms in TP53 are associated with risk and survival of osteosarcoma in a Chinese population.International journal of clinical and experimental pathology · 2015
    Article
  10. Impact of MDM2 309T>G polymorphism on sarcomagenesis.International journal of clinical and experimental medicine · 2015
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Helena S ThurowMolecular and Cellular Oncology Research Group, Biotechnology Unit, Technology Development Center (CDTec), Federal University of Pelotas (UFPel), Pelotas, RS, 96010-900, Brazil.
Fernando P Hartwig
Clarice S Alho
Deborah S B S Silva
Rafael Roesler
Ana Lucia Abujamra
Caroline Brunetto de Farias
Algemir Lunardi Brunetto
Bernardo L Horta
Odir A Dellagostin
Tiago Collares
Fabiana K Seixas
Universidade Federal de Pelotas · BRHospital de Clínicas de Porto Alegre · BRPontifícia Universidade Católica do Rio Grande do Sul · BRTranslational Research in Oncology · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Ewing Sarcoma is an important tumor of bone and soft tissue. The SNPs Arg72Pro of TP53 and T309G of MDM2 have been associated with many cancer types and have been differently distributed among populations worldwide. Based on a case-control design, this study aimed to assess the role of these SNPs in 24 Ewing Sarcoma patients, compared to 91 control individuals. DNA samples were extracted from blood and genotyped for both SNPs by PCR-RFLP and confirmed by DNA sequencing. The results showed an association between the G allele of the T309G and Ewing Sarcoma (P=0.02). Comparing to the TT carriers, the risk of G allele carriers was 3.35 (95% CI=1.22-9.21) with P=0.02. At the genotypic level, an association of the TT genotype with the control group (P=0.03) was found. Comparing to the TT genotype, the risk of TG and GG was 2.97 (95% CI=1.03-8.58) with P=0.04 and 5.00 (95% CI=1.23-20.34) with P=0.02, respectively. No associations regarding the Arg72Pro SNP were found. Considering that the T309G has been associated with several types of cancer, including sarcomas, our results indicate that this SNP may also be important to Ewing Sarcoma predisposition.

Indexed as

Amino Acid SubstitutionBrazilCase-Control StudiesGenetic Association StudiesGenetic Predisposition to DiseaseGenotypeHumansLogistic ModelsPolymerase Chain ReactionPolymorphism, Restriction Fragment LengthPolymorphism, Single NucleotideProto-Oncogene Proteins c-mdm2Sarcoma, EwingSequence Analysis, DNATumor Suppressor Protein p53MDM2 protein, humanProto-Oncogene Proteins c-mdm2TP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID23661019
OpenAlexW2013517211

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.